Takeda Pharmaceutical To Release Sustained-Release Morphine Hydrochloride Capsule
Main Category: Cancer / OncologyAlso Included In: Pain / Anesthetics
Article Date: 17 Apr 2006 - 0:00 PDT
email to a friend 
printer friendly 
view / write opinions 
rate articleCurrent Article Ratings:
| Patient / Public: |  |
1 (1 votes) |
| Health Professional: |  |
|
| Article Opinions: | 0 posts |
Tokyo, April, 2006 (JCN) - Takeda Pharmaceutical has launched Passif, its proprietary sustained release capsule of morphine hydrochloride.
Available in three dosages 30mg, 60mg and 120mg, the new agent is indicated for the treatment of pain control for cancer patients with moderate to severe pain. It can exert beneficial effects with a once-a-day dosage.
By Aki Tsukioka, JCN Staff Writer
Company Profile
Copyright © 2006 JCN. All rights reserved. A division of Japan Corporate News Network KK.
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Cancer / Oncology headlines email to a friend printer friendly version
weekly newsletter daily news alerts
personalize your news
rss feeds
back to top
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2009 MediLexicon International Ltd |
